KALV
KalVista Pharmaceuticals, Inc. · Healthcare
Chief Development Officer Christopher Yea sold $59K of KalVista Pharmaceuticals, Inc.
Sold$58,535
$8.23Price
7,113Shares
−13%Stake
What KALV did after the filing
- The stock from Tue, Nov 21 close, $7.73
- +47.1%
- S&P 500, same days
- +3.7%
Measured over 30 trading days, to the Jan 5 close.
Traded Mon, Nov 20. Filed Tue, Nov 21, 11:32 AM ET, during the session. Returns use the Nov 21 close and the Jan 5 close. Not investment advice.